CelLBxHealth guides for £2.1 million revenue in 2026, 50% growth
CelLBxHealth PLC expects at least £2.1 million in revenue for 2026, a 50% increase from 2025's £1.4 million, as its commercial pipeline expanded 22% in the last quarter following a year-long restructuring that reduced costs and shifted strategy toward pharmaceutical partnerships.
CelLBxHealth PLC (AIM:) issued 2026 revenue guidance of at least £2.1 million, representing growth of at least 50% from last year's £1.4 million, as the circulating tumour cell diagnostics company pivots toward pharmaceutical and diagnostic partnerships [1]. The AIM-listed firm disclosed that its commercial pipeline has expanded 22% over the last quarter [1].
The guidance follows a year-long restructuring during 2025 in which CelLBxHealth cut its cost base substantially and recruited new leadership to shift away from research income toward a partnership-focused strategy centred on pharmaceutical and diagnostic companies [1]. The company emerged from the process "sharper and leaner," positioning itself to capitalize on the expanded pipeline [1].
Continue reading
2 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.